Marty Chilberg
Long only, special situations, research analyst, healthcare

Sequenom: A Reversal Of Misfortune

On January 7th 2013, Sequenom (NASDAQ:SQNM) was torpedoed when Illumina (NASDAQ:ILMN) announced their acquisition of Verinata and their prenatal diagnostic screen, Verifi. This decision was widely considered a head scratcher. Verifi at the time had around 7% US market share, yet Illumina paid $350 million plus an opportunity to earn another $100 million based upon certain deliverables. What made this announcement so curious was that Illumina already appeared to be in the driver's seat as the best derivative investment for this nascent market. Everyone else was fighting tooth and nail to survive. Patent survivability was being attacked in the courts and there was a constant fight for reimbursements. Illumina on the other hand, sold the sequencing...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details